- Home
- ELVN vs CNNE Comparison
ELVN vs CNNE Comparison
Compare ELVN & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- CNNE
- Stock Information
- Founded
- ELVN 2016
- CNNE 2014
- Country
- ELVN United States
- CNNE United States
- Employees
- ELVN N/A
- CNNE N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- CNNE Restaurants
- Sector
- ELVN Health Care
- CNNE Consumer Discretionary
- Exchange
- ELVN Nasdaq
- CNNE Nasdaq
- Market Cap
- ELVN 1.1B
- CNNE 1.3B
- IPO Year
- ELVN 2020
- CNNE N/A
- Fundamental
- Price
- ELVN $22.47
- CNNE $20.00
- Analyst Decision
- ELVN Strong Buy
- CNNE Buy
- Analyst Count
- ELVN 5
- CNNE 2
- Target Price
- ELVN $37.80
- CNNE $27.00
- AVG Volume (30 Days)
- ELVN 204.7K
- CNNE 291.7K
- Earning Date
- ELVN 11-13-2024
- CNNE 11-12-2024
- Dividend Yield
- ELVN N/A
- CNNE 1.80%
- EPS Growth
- ELVN N/A
- CNNE N/A
- EPS
- ELVN N/A
- CNNE N/A
- Revenue
- ELVN N/A
- CNNE $461,900,000.00
- Revenue This Year
- ELVN N/A
- CNNE N/A
- Revenue Next Year
- ELVN N/A
- CNNE $0.42
- P/E Ratio
- ELVN N/A
- CNNE N/A
- Revenue Growth
- ELVN N/A
- CNNE N/A
- 52 Week Low
- ELVN $10.90
- CNNE $16.94
- 52 Week High
- ELVN $30.03
- CNNE $22.99
- Technical
- Relative Strength Index (RSI)
- ELVN 39.53
- CNNE 40.68
- Support Level
- ELVN $21.84
- CNNE $19.54
- Resistance Level
- ELVN $24.42
- CNNE $20.83
- Average True Range (ATR)
- ELVN 1.59
- CNNE 0.44
- MACD
- ELVN -0.05
- CNNE -0.18
- Stochastic Oscillator
- ELVN 18.27
- CNNE 21.30
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFE, Corporate and Other Affiliate Elimination. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.